T-cell Engagers Market to Record US$ 58.04 billion by 2035.
The global T-cell Engagers Market is projected to reach US$ 58.04 billion by 2035, growing at a CAGR of 22.73% from its 2025 valuation of US$ 7.27 billion. Key industry developments include advancements in BiTE platforms, expansion of manufacturing capabilities, and strategic collaborations among major pharmaceutical companies like Amgen, Johnson & Johnson, and Regeneron. The market's growth is driven by increasing adoption, investments, and innovations in oncology immunotherapy and autoimmune disease treatments across various regions.
MAY 7·Stock Titan▼
Xencor (NASDAQ: XNCR) posts deeper Q1 2026 loss amid royalty dispute and Zenas write-down
Xencor (NASDAQ: XNCR) reported a significantly wider loss in Q1 2026, with revenue dropping to $4.5 million from $32.7 million year-over-year. This was primarily due to a lack of repeating Incyte milestones, reduced Ultomiris royalty revenue, and a $51.9 million unrealized loss on its equity stake in Zenas BioPharma. The company is also engaged in a royalty dispute with Alexion concerning Ultomiris U.S. payments, leading to a reversal of $6.6 million in previously recorded royalties.
MAY 7·Yahoo Finance UK▼
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) reported a wider-than-expected Q1 loss of $1.71 per share, significantly missing the Zacks Consensus Estimate of a $0.65 loss, and also lagged revenue estimates with $4.52 million against an expected 75.38% higher figure. Despite beating EPS estimates three times in the last four quarters, the revenue performance was a miss for the quarter ended March 2026. The stock currently holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.
